Many pharmaceutical companies took a fine in a few months!

Since the second half of 2021, news about drug companies' fines have been coming in continuously.
The reasons can be described as various: violations of laws and regulations in the production process, touching the "red line" of anti-monopoly, selling inferior drugs, etc.
, in general, the trend is increasing.
Under strict supervision, standardized operation of pharmaceutical companies is the way to survive
.
Many pharmaceutical companies took a fine in a few months! Industry: Standardized operation is the way to survive (Image source: Pharmaceutical Network) On December 1, a pharmaceutical company in Guizhou issued an announcement regarding the receipt of an administrative penalty decision by a controlling subsidiary.
When the controlling subsidiary produces drugs, it does not strictly follow the registration requirements.
The process organized production and was fined 32.
068 million yuan
.
However, the company also stated that after the incident, the company’s management attached great importance to it and set up a special working group to conduct a strict self-examination of the company’s and its subsidiaries’ existing production standard work processes, sort out related defects, and strictly control production and operation risks
.
Recently, the Hunan Provincial Food and Drug Administration issued two administrative penalty decisions
.
For the production and sales of inferior drugs, a pharmaceutical company in Hunan Province was given a warning and a fine of 100,000 yuan; another pharmaceutical company was imposed a confiscation of illegal income of 2,211.
00 yuan and a double fine of 4242.
00 yuan for the illegal production and sales of drugs.
The total amount of the above fines and confiscated 6363.
00 yuan
.
On November 19, the Anhui Provincial Food and Drug Administration issued administrative punishment information.
Among them, a pharmaceutical company was fined 1,701,335 million yuan for suspected production and sales of inferior drugs; a medicinal wine Cistanche fruit produced by a decoction piece company was inspected and [inspection] was not in compliance According to regulations, a total of 164,600 fines and confiscations were imposed; another enterprise producing and selling inferior medicines of traditional Chinese medicine was fined 27,746 yuan
.
On November 18th, on the day that the National Anti-Monopoly Bureau was officially listed, the anti-monopoly guidelines in the field of APIs were also released
.
On the same day, a company in Nanjing was fined 6.
5837 million yuan by the Shanghai Market Supervision Bureau for abusing its market dominance by selling raw materials at unfairly high prices and adding unreasonable trading conditions.

.
On November 9, the Fujian Provincial Food and Drug Administration issued an administrative penalty information disclosure form.
A pharmaceutical company was punished by the Food and Drug Administration for repeatedly selling drugs without obtaining the "Drug Business License": the party was ordered to close Drug business; confiscated 115 bottles of unsold drugs 0.
9% sodium chloride injection and illegal gains of 36,270.
1 yuan; fined 1.
5 million yuan
.
The above-mentioned fines and confiscated amounts totaled 1.
5363 million yuan
.
In addition, within a few months, the Food and Drug Administration of Tianjin, Shandong Province and many other places have also issued information disclosure forms for administrative penalty cases, involving many pharmaceutical companies that have been fined for violations and the fines have been large or small
.
Judging from the severity of the fines imposed on the above-mentioned pharmaceutical companies, pharmaceutical companies that produce inferior drugs are all paid large fines.
This is mainly related to the implementation of the new "Drug Administration Law
.
" It is understood that since the issuance of the new regulations, the cost of illegally producing substandard and counterfeit medicines by pharmaceutical companies has greatly increased.
According to the new version of the "Drug Administration Law", the minimum fine for selling counterfeit drugs is 1.
5 million, and the minimum fine for retailing substandard drugs is 10.
Million
.
Earlier, there were reports that a pharmacy was fined 150,000 for selling 6 yuan of inferior drugs.
The fine was equivalent to 250,000 times the value of the goods.
From the data, it can be seen that the gains of the pharmaceutical companies outweigh the losses
.
According to the industry, if pharmaceutical companies continue to touch the "red line", cases of penalties for millions of dollars will emerge in the future
.
In the context of increasing industry supervision and increasing frequency of supervision, enterprises in the pharmaceutical industry need to stop the illegal sales of inferior drugs in a timely manner, pay attention to quality management and production management, and conduct regular on-site GMP compliance inspections.
Only standard operations can go.
Go further
.